Teva ADS removed from NYSE stock listing

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is having its American Depositary Shares, each representing one ordinary share, removed from listing and registration on the New York Stock Exchange LLC under Section 12(b) of the Securities Exchange Act of 1934.

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is having its American Depositary Shares, each representing one ordinary share, removed from listing and registration on the New York Stock Exchange LLC under Section 12(b) of the Securities Exchange Act of 1934. The New York Stock Exchange filed a Form 25, certifying it has complied with its own rules to strike this class of securities from listing under 17 CFR 240.12d2-2(b). The company is stated to have complied with the Exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of this class of securities from listing and registration.

Key Figures

Commission File Number: 001-16174 Principal office telephone number: 972 3 914-8213 ADS to Ordinary Share ratio: 1 ADS per 1 Ordinary Share

3 metrics

Commission File Number 001-16174 File number associated with Teva’s Section 12(b) registration being removed

Principal office telephone number 972 3 914-8213 Telephone number for Teva’s principal executive offices in Tel Aviv

ADS to Ordinary Share ratio 1 ADS per 1 Ordinary Share Each American Depositary Share represents one ordinary share

Key Terms

Form 25, Section 12(b), American Depositary Shares, voluntary withdrawal, +2 more

6 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) regulatory

"listing and/or registration under Section 12(b) of the Securities Exchange Act"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

American Depositary Shares financial

"American Depositary Shares, each representing one Ordinary Share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

voluntary withdrawal regulatory

"governing the voluntary withdrawal of the class of securities"

17 CFR 240.12d2-2(b) regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"

17 CFR 240.12d2-2(c) regulatory

"the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TEVA announce regarding its NYSE listing in this Form 25?

The filing states that the New York Stock Exchange LLC submitted Form 25 to remove Teva Pharmaceutical Industries Ltd.’s American Depositary Shares from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.

Which TEVA securities are being removed from the NYSE listing?

The removal applies to American Depositary Shares of Teva Pharmaceutical Industries Ltd., with each ADS representing one Ordinary Share, as described in the document.

Who filed the Form 25 related to TEVA and what did they certify?

The New York Stock Exchange LLC filed the Form 25, certifying it has complied with its rules to strike this class of Teva securities from listing under 17 CFR 240.12d2-2(b).

Did TEVA comply with requirements for voluntary withdrawal from NYSE listing?

Yes. The document states that the issuer has complied with the Exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration.

Under which regulatory provisions is TEVA’s NYSE delisting taking place?

The delisting proceeds under Section 12(b) of the Securities Exchange Act and implementing rules including 17 CFR 240.12d2-2(b) and 17 CFR 240.12d2-2(c), as referenced in the notification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 02:33 PM Accepted by SEC EDGAR 09/14/2026 - 02:32 PM Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-16174

Issuer:	TEVA PHARMACEUTICAL INDUSTRIES LTD
Exchange:	NEW YORK STOCK EXCHANGE LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	124 Dvora Hanevia St
	Tel Aviv		4951033
Telephone number:					972 (3) 914-8213

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

American Depositary Shares, each representing one Ordinary Share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-09-14	By	Victoria Paper		Manager, Market Watch
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.